Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:BCRXNASDAQ:LGNDNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$31.42+0.5%$29.71$22.90▼$36.45$5.18B0.511.75 million shs83,074 shsBCRXBioCryst Pharmaceuticals$11.11-0.7%$8.79$5.92▼$11.33$2.33B1.083.02 million shs520,642 shsLGNDLigand Pharmaceuticals$102.67+0.3%$104.39$77.43▼$129.90$1.98B0.87115,877 shs11,439 shsMNKDMannKind$4.46+0.8%$4.61$4.05▼$7.63$1.35B1.142.37 million shs183,301 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-0.06%+4.58%-1.60%-11.37%+29.99%BCRXBioCryst Pharmaceuticals+4.29%+3.71%+25.31%+39.01%+64.80%LGNDLigand Pharmaceuticals+0.70%+0.70%-6.44%-11.32%+16.43%MNKDMannKind+3.03%+5.24%-11.60%-14.17%-5.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.5773 of 5 stars3.43.00.04.23.41.71.9BCRXBioCryst Pharmaceuticals4.4771 of 5 stars4.41.00.04.23.91.70.6LGNDLigand Pharmaceuticals4.8327 of 5 stars3.53.00.04.44.13.31.9MNKDMannKind2.9921 of 5 stars3.61.00.00.02.91.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.77Moderate Buy$38.8523.65% UpsideBCRXBioCryst Pharmaceuticals 2.89Moderate Buy$16.5649.06% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1442.34% UpsideMNKDMannKind 3.25Buy$10.00124.47% UpsideCurrent Analyst Ratings BreakdownLatest MNKD, ALKS, BCRX, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/7/2025BCRXBioCryst PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.005/6/2025BCRXBioCryst PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $17.005/6/2025BCRXBioCryst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.42$2.36 per share13.32$9.05 per share3.47BCRXBioCryst Pharmaceuticals$503.49M4.62N/AN/A($2.22) per share-5.00LGNDLigand Pharmaceuticals$181.49M10.91$4.21 per share24.39$40.39 per share2.54MNKDMannKind$297.60M4.55N/AN/A($0.91) per share-4.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0914.4822.932.2023.57%30.80%19.09%7/23/2025 (Estimated)BCRXBioCryst Pharmaceuticals-$226.54M-$0.26N/AN/AN/A-30.01%N/A-24.06%8/4/2025 (Estimated)LGNDLigand Pharmaceuticals$52.15M-$7.1240.9027.67N/A29.68%4.95%4.39%8/5/2025 (Estimated)MNKDMannKind-$11.94M$0.1063.6419.37N/A8.07%-17.74%8.68%8/6/2025 (Estimated)Latest MNKD, ALKS, BCRX, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.042.65BCRXBioCryst PharmaceuticalsN/A2.782.73LGNDLigand PharmaceuticalsN/A12.4911.81MNKDMannKindN/A4.544.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BCRXBioCryst Pharmaceuticals85.88%LGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%BCRXBioCryst Pharmaceuticals4.80%LGNDLigand Pharmaceuticals5.90%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,280164.90 million154.66 millionOptionableBCRXBioCryst Pharmaceuticals530209.25 million197.19 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.78 millionOptionableMNKDMannKind400303.93 million267.51 millionOptionableMNKD, ALKS, BCRX, and LGND HeadlinesRecent News About These Companies180 Wealth Advisors LLC Has $11.04 Million Holdings in MannKind Co. (NASDAQ:MNKD)June 2 at 7:13 AM | marketbeat.comMannKind Co. (NASDAQ:MNKD) Given Average Recommendation of "Buy" by BrokeragesMay 31, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Given Average Recommendation of "Buy" by AnalystsMay 30, 2025 | americanbankingnews.comINDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29May 27, 2025 | globenewswire.comVoloridge Investment Management LLC Has $6.86 Million Stake in MannKind Co. (NASDAQ:MNKD)May 27, 2025 | marketbeat.comNuveen Asset Management LLC Lowers Stake in MannKind Co. (NASDAQ:MNKD)May 27, 2025 | marketbeat.comMannKind: Why I'm Still Bullish Despite Tyvaso DPI CompetitionMay 27, 2025 | seekingalpha.comMannKind (NASDAQ:MNKD) versus Edesa Biotech (NASDAQ:EDSA) Head to Head ContrastMay 26, 2025 | americanbankingnews.comTwo Sigma Advisers LP Boosts Stock Holdings in MannKind Co. (NASDAQ:MNKD)May 24, 2025 | marketbeat.comTwo Sigma Investments LP Boosts Stock Holdings in MannKind Co. (NASDAQ:MNKD)May 24, 2025 | marketbeat.comMan Group plc Purchases 219,891 Shares of MannKind Co. (NASDAQ:MNKD)May 24, 2025 | marketbeat.comMillennium Management LLC Has $22.17 Million Stake in MannKind Co. (NASDAQ:MNKD)May 23, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Acquired by Deutsche Bank AGMay 23, 2025 | marketbeat.comBank of America Corp DE Raises Position in MannKind Co. (NASDAQ:MNKD)May 22, 2025 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) EVP Sells 2,345 Shares of StockMay 21, 2025 | insidertrades.comNomura Holdings Inc. Sells 2,792,237 Shares of MannKind Co. (NASDAQ:MNKD)May 21, 2025 | marketbeat.comMannKind Stockholders Approve Board and CompensationMay 19, 2025 | tipranks.comDavid Thomson Sells 32,179 Shares of MannKind Co. (NASDAQ:MNKD) StockMay 16, 2025 | insidertrades.comMannKind Co. (NASDAQ:MNKD) Stake Lowered by Parkman Healthcare Partners LLCMay 16, 2025 | marketbeat.comCantor Fitzgerald Expects Stronger Earnings for MannKindMay 16, 2025 | marketbeat.comBNP Paribas Financial Markets Boosts Stock Position in MannKind Co. (NASDAQ:MNKD)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNKD, ALKS, BCRX, and LGND Company DescriptionsAlkermes NASDAQ:ALKS$31.42 +0.15 (+0.47%) As of 10:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.BioCryst Pharmaceuticals NASDAQ:BCRX$11.11 -0.08 (-0.74%) As of 10:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Ligand Pharmaceuticals NASDAQ:LGND$102.67 +0.32 (+0.31%) As of 10:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$4.46 +0.04 (+0.79%) As of 10:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
